- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00756288
Photo-therapy With a Topical Retinoid Versus Photo-therapy Alone for Actinic Keratoses
December 2, 2021 updated by: Murad Alam, Northwestern University
A Randomized Controlled Paired Comparison of Photo-therapy With a Topical Retinoid Cream Pretreatment Versus PDT Alone for Actinic Keratoses
Evaluating safety and efficacy of the use of topical retinoid with photodynamic therapy for the treatment of actinic keratoses.
Study Overview
Status
Withdrawn
Conditions
Detailed Description
Evaluating safety and efficacy of the use of topical retinoid with photodynamic therapy vs photodynamic therapy alone for the treatment of actinic keratoses.
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Adults aged 18-80 years old
- Subjects with AK lesions who will receive PDT
- Subjects with AK lesions in two areas other than face and scalp each with a surface area of 10cm2 or greater and at least 3 clinically diagnosed non-hypertrophic AK lesions in each
- Subjects in good health
- Subjects with willingness and the ability to understand and provide informed consent
Exclusion Criteria
- Subjects who are pregnant or lactating
- Subjects with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis
- Subjects with use of photosensitizing drugs within 1 week of study start
- Subjects with use of topical medications such as corticosteroids, alpha-hydroxyacids or retinoids 2 weeks before study entry
- Subjects who received previous treatment of target AKs within 4 weeks
- Subjects who are unable to understand the protocol or give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Topical retinoid and Light therapy with photosensitizing agent
|
Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
|
Active Comparator: 2
Light therapy with photosensitizing agent
|
Photo-therapy with sensitizing agent - apply to AKs at week 4
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Live blinded rater and blinded photo rater analysis of areas at week 0 and week 6 for erythema, edema, crusting, ulceration, palpability, need to cease/delay treatment, and overall response in reduction of number of actinic keratoses (AKs).
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subjects will assess pain, burning and itching on a scale of 0-3 at week 0, during retinoid treatment, during photo-therapy, one day after, and week 6. Also, principal investigator will evaluate adverse events at week 6.
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Murad Alam, MD, Northwestern University Department of Dermatology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Anticipated)
December 1, 2016
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
September 19, 2008
First Submitted That Met QC Criteria
September 19, 2008
First Posted (Estimate)
September 22, 2008
Study Record Updates
Last Update Posted (Actual)
December 6, 2021
Last Update Submitted That Met QC Criteria
December 2, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU2574
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratoses
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
-
PeplinCompleted
-
Bispebjerg HospitalCompletedActinic KeratosesDenmark
Clinical Trials on Topical retinoid and blue-light therapy with photosensitizing agent
-
The Center for Clinical and Cosmetic ResearchSun Pharmaceutical Industries LimitedRecruitingFacial Cutaneous Squamous Cell Carcinoma in SituUnited States
-
Dartmouth-Hitchcock Medical CenterDUSA Pharmaceuticals, Inc.CompletedActinic CheilitisUnited States
-
Northwestern UniversityActive, not recruiting
-
University of California, San FranciscoCompleted
-
Medical Dermatology SpecialistsDUSA Pharmaceuticals, Inc.CompletedActinic Keratosis | Skin Cancer | Non-melanoma Skin Cancer | Sun Damaged SkinUnited States
-
DUSA Pharmaceuticals, Inc.Completed
-
DUSA Pharmaceuticals, Inc.Completed
-
Edward Maytin, MD, PhDDUSA Pharmaceuticals, Inc.CompletedBasal Cell Nevus SyndromeUnited States
-
DUSA Pharmaceuticals, Inc.CompletedActinic KeratosisUnited States
-
DUSA Pharmaceuticals, Inc.Completed